** Shares of medical device maker Tandem Diabetes Care TNDM.O down 24% at $25.50
** Company late on Wednesday forecast 2025 sales between $997 mln and $1.007 bln vs. analysts' average estimate of $1.004 billion, according to data compiled by LSEG
** Says "muted seasonality" and "shipping delays" led to softness in demand for co's insulin pumps towards the end of Q4 and expects salesforce disruptions -TNDM
** The 2025 outlook reflects the seasonal trends extending into Q1 - RBC Capital analysts
** "What will likely cause investor consternation is the lower-than-anticipated Q1 2025 revenue guidance and the implied ramp through the rest of the year" -Brokerage Citi
** Company sees Q1 sales to be about $219 million to $224 million compared to analysts' estimate of $221 million
** TNDM has risen 16.4% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。